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Characterization of a mutant type-i angiotensin It receptor. We have
used PCR to amplify the rat AT1 receptor from liver mRNA. The receptor
DNA was subcloned into pcDNAI and a number of individual clones were
transiently expressed in COS-7 cells. These individual receptors were
characterized by binding of [125!] Sar1, 11e8-angiotensin II. It was found
that one of the AT1 receptor clones did not bind the radiolabeled
angiotensin II ligand. The mutant clone was analyzed by nucleotide
sequencing. This analysis revealed that the clone has a single amino acid
substitution in the third transmembrane domain of the receptor; a leucine
at position 112 was changed to a proline. At this stage it is not known
whether the mutant receptor is the result of a PCR artifact or an allelic
difference.
The type-i angiotensin I! receptor is a member of the G
protein-coupled receptor family which contains seven transmem-
brane domains. These receptors are able to recognize and bind
specific hormones or regulatory molecules due to unique struc-
tural elements which comprise the ligand binding domain. Recent
data on some family members, in particular the 13-adrenergic
receptors, implicate the transmembrane regions in ligand binding
[1]. These data include peptide mapping with radiolabeled ligands
[2], mutational studies [3—5], and localization of fluorescent
ligands within the membrane [6]. In the present study we show
that a rat AT1 receptor with a mutation in the third transmem-
brane domain does not bind radiolabeled angiotensin II.
Methods
RNA isolation and PCR amplication
Total RNA was isolated from rat liver by the guanidium
thiocyanate/CsCI cushion procedure [7]. RNA was reverse-tran-
scribed in a 20 j.Li reaction containing 20 mivi Tris-HC1 (pH 8.3),
100 mM KC1, 10 mi MgCI2, 10 m'vi dithiothreitol (DTT), 1 m of
each dNTP, 10 U RNasin, 14 U AMV reverse transcriptase and 50
ng specific primer (5'-GGTAAACATACA1TGCC-3'). This primer
is complimentary to position 1890 of the rat AT1 receptor cDNA
sequence [8]. An aliquot of cDNA (5 p1) was used in a 100 p1 PCR
reaction containing 20 mt's Tris-HCI (pH 8.3), 40 mt's KCI, 2 m
MgCl2, 0.01% gelatin, 0.05% Tween 20, 0.2 xM oligonucleotide
primers and 2 U Taq polymerase for 40 cycles (94°C for 1 mm,
55°C for 1 mm and 72°C for 3 mm). The PCR primers were (5'-
GTGGATITTCGAATAGTGTCTGAGAC-3') and (5'-TAAA-
GATG TTCACGTATGTGGAG AA-3') which corresponded to
positions —40 and 1840 of the rat AT1 receptor cDNA sequence
[8].
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Subcloning and nucleotide sequencing
PCR product DNA was subcloned into the expression vector
pcDNA1. DNA templates were sequenced by the dideoxy chain
termination procedure using specific oligonucleotide primers, T7
DNA polymerase and [a-35S]dATP.
Expression and labeling ofAT1 receptors
Miniprep DNA from individual clones was transfected into
COS-7 cells by electroporation. Approximately 1.5 X 106 COS-7
cells in 200 j.d phosphate-buffered saline (PBS) were mixed with
20 pl DNA (4 jxg). Cells were electroporated at 300 V and 125 x
FD in 0.4 cm cuvettes and cultured in 2 ml RPMI containing 10%
fetal calf serum in glass slide-based flaskettes.
After 48 to 72 hours the medium was removed and the
transfected monolayers were assayed for binding of [1251] Sar',
11e8-angiotensin II ('—2000 Ci/mmol, Amersham) for 60 minutes
at 20°C. The monolayers were washed twice in medium, fixed,
then analyzed by phosphor imaging on a Fuji BAS 2000, and
liquid emulsion autoradiography.
Results
PCR amplification of the rat AT1 receptor
We used PCR to amplify the rat AT1 receptor from liver
mRNA. A set of synthetic oligonucleotide primers were made
which corresponded to the previously published eDNA sequence
[8]. These primers generated a 1.8 kb DNA fragment which
contained the entire coding region and 700 bp of 3' untranslated
region. This PCR product was subcloned into the mammalian
expression vector pcDNA1. Individual clones were isolated and
subjected to partial nucleotide sequencing which confirmed the
amplification of the rat AT1 receptor and the correct orientation
in the expression vector.
Angiotensin II binding
A number of individual receptor clones were transiently ex-
pressed in COS-7 cells and assayed for binding of [1251] Sar1,
11e8-angiotensin II. Binding was analyzed by phosphor imaging on
a BAS 2000 and liquid emulsion autoradiography. Of three clones
which were analyzed, two receptor clones bound the ligand and
one clone did not bind the radiolabeled angiotensin II ligand. This
result was repeated on three separate occasions. An example of
ligand binding is shown in Figure 1. The non-binding receptor
clone did not exhibit any detectable ligand binding, even after
longer exposure times. This mutant clone was analyzed by nude-
otide sequencing.
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SNucleotide analysis of mutant receptor
The mutant receptor clone and a clone which did bind the
ligand were analyzed by nucleotide sequencing. The entire coding
region of each clone was characterized. This analysis revealed that
the mutant clone has a C to T transition at nucleotide 334. This
change results in a substitution of proline for leucine at amino
acid position 112 in the third transmembrane domain (Fig. 2).
This leucine is located approximately half way in the transmem-
brane domain, and is conserved in all mammalian AT1 receptors
so far studied.
Discussion
In this study we show that a rat AT1 receptor with a mutation
in the third transmembrane domain does not bind radiolabeled
angiotensin II. The site of the mutation in the receptor correlates
with data on other G protein-coupled receptors, which indicates
that the transmembrane domains are closely involved in ligand
binding.
Mutagenesis studies on the -adrenergic receptor have demon-
strated that large portions of the extracellular and intracellular
hydrophilic regions can be deleted without markedly altering
ligand binding [9]. Also, physical evidence has been obtained
which indicates that the ligand-binding site of the 13-adrenergic
receptor is buried within the lipophilic core of the protein [6].
These studies used a fluorescent ligand and it was estimated that
the binding site was approximately one-third of the way down the
helical core of the receptor. Mutational studies also indicate that
conserved transmembrane aspartate residues may play a role in
ligand binding in both the -adrenergic [3] and muscarinic
acetylcholine receptors [10, 11]. It is thought that acidic residues,
such as aspartate and glutamate, are necessary in key positions to
maintain the receptor in an inactive conformation. This could
occur via a salt bridge between the acidic residue and a basic
residue in another transmembrane domain. Thus specific intramo-
lecular interactions could maintain the receptor in a constrained,
inactive state until relieved by ligand binding.
The mutation described in this study is the substitution of a
proline for leucine at position 112 in the third transmembrane
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domain. Both leucine and proline are neutral, hydrophobic amino
acids, therefore the subsitution is unlikely to effect local charge
interactions or insertion into a hydrophobic outer membrane.
However proline is known as an a-helix breaker and it could
provide an abnormal kink in the transmembrane helix. This kink
could disrupt specific intramolecular interactions which maintain
the receptor in an inactive state. If this were the case then the
conformation of the ligand binding pocket might be altered, thus
resulting in a receptor which doesn't bind [1251] Sar1, Ile8-
angiotensin II. The leucine at position 112 is conserved in all
mammalian AT1 receptors so far studied and in the Xenopus laevis
AT receptor.
Recently several mutations have been described in which G
protein-coupled receptors don't bind ligand but are constitutively
active. These receptors include Luteinizing hormone [12], MSH
[13] and rhodopsin [14]. In the case of the MSH receptor one of
the mutations is a leucine to a proline at the beginning of the
second transmembrane domain. This is the same substitution seen
here in the AT1 receptor. It is thought that the mutation in the
MSH receptor disrupts the a-helical transmembrane domain
sufficiently to prevent a glutamate at position 92 from forming a
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Fig. 1. Binding of [1251] Sar', 11e8-angiotensin II to COS-7 cells transfected
with AT1 receptor expression vectors. A BAS 2000 phosphor image of
transfected cells grown on microscope slides; mutant and wild type
receptors as indicated (X 4).
NH2
Leu—*Pro
OOH
Fig. 2. (A) The T to C nucleotide change which results in the substitution of
a proline for a leucine at position 112. (B) Schematic representation of the
membrane topology of the AT1 receptor, indicating the position of Leu
112 in the middle of the third trarismembrane domain.
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salt bridge necessary for maintenance of the inactive conforma-
tion. The mutations in the LH receptor and rhodopsin which lead
to the constitutive activation are also found in the transmembrane
domains. This raises the possibility that the mutant AT1 receptor
described here could be constitutively active. Further experiments
will have to be performed to determine whether this is the case.
At this stage it is not known whether the mutant AT1 receptor
is the result of a PCR amplification artifact or an allelic difference.
Also, there is the possibility that the mutation results in a greatly
reduced amount of receptor on the cell surface. This is unlikely,
however, given that the substituted amino acid has the same
neutral charge and hydrophobicity as the native residue. The
characterization of this Leu 112 to Pro mutation provides a
valuable insight into the significance of a particular amino acid
residue in the third transmembrane domain.
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